Lymphocyte Proliferation, Mitogen Induced, by Flow Cytometry (48-Hr Critical Room Temp)
Primarily for evaluating lymphocyte function in patients with suspected cellular immune dysfunction, such as primary and secondary immunodeficiencies. Other uses include monitoring lymphocyte recovery and competence after hematopoietic stem cell transplantation and monitoring lymphocyte function during immunosuppressive therapy.
Cell Culture/Flow Cytometry
Collect control specimen from a healthy individual unrelated to patient.
Patient and control specimens must be collected ONLY on Wednesdays or Thursdays AND shipped directly to ARUP the same calendar day to meet the strict 48-hour stability requirement.
Green (sodium heparin) (patient) AND green (sodium heparin) (control) only on Wednesdays or Thursdays.
Transport 10 mL whole blood (patient) AND 10 mL whole blood (control) in original collection tubes. (Min: 7 mL (patient) AND 7 mL (control)). Infant Minimum: 3 mL (patient AND 7 mL (control).
Do not refrigerate or freeze. LIVE LYMPHOCYTES REQUIRED.
CRITICAL ROOM TEMPERATURE.
Must be collected and shipped directly to ARUP the same calendar day.
Refrigerated or frozen specimens.
Do not collect or ship on, or the day before, holidays.
Ambient: 48 hours; Refrigerated: Unacceptable; Frozen: Unacceptable
|CD45 Pos Cells||39.7% or greater||15.5% or greater||10.0% or greater|
|CD3 Pos Cells||42.5% or greater||17.4% or greater||8.0% or greater|
|CD19 Pos Cells||51.9% or greater||N/A||6.3% or greater|
This test measures lymphocyte proliferation in response to stimulation with nonspecific mitogens phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM), determined by flow cytometry. Proliferating cells are detected by fluorescent labeling. Results are reported as percent proliferating cells of total specific cell populations.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
|Component Test Code*||Component Chart Name||LOINC|
|3001322||CD45+ Cell Proliferation by PHA||69038-8|
|3001323||CD3+ Cell Proliferation by PHA||69013-1|
|3001324||CD19+ Cell Proliferation by PHA|
|3001325||CD45+ Cell Proliferation by Con A|
|3001326||CD3+ Cell Proliferation by Con A|
|3001327||CD45+ Cell Proliferation by PWM||69019-8|
|3001328||CD3+ Cell Proliferation by PWM||69020-6|
|3001329||CD19+ Cell Proliferation by PWM||69037-0|
|3001336||Lymphocyte Proliferation-Mitogen, Interp||53810-8|